ReviewNeuropsychiatric disease and treatment2017
Methylphenidate dose optimization for ADHD treatment: review of safety, efficacy, and clinical necessity.
Review in Neuropsychiatric disease and treatment, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 46 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effects of a Single Dose of Methylphenidate on Motor Performance
The Effects of Methylphenidate (MPH) and Non-invasive Brain Stimulation (tDCS) on Inhibitory Control Children With Attention-Deficit/Hyperactivity Disorder (ADHD)
Who cites it
46 citing papers in PubMed, 3 syntheses or guidelines pooled it, 96 citations in OpenAlex.
- The impact of long-term exercise on motor skills in children with ADHD: a three-level meta-analysis.BMC pediatrics · 2025Pooled it
- Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.The Cochrane database of systematic reviews · 2022Pooled it
- Therapeutic effects of methylphenidate for attention-deficit/hyperactivity disorder in children with borderline intellectual functioning or intellectual disability: A systematic review and meta-analysis.Scientific reports · 2019Pooled it
- Effects of single-dose methylphenidate on motor performance in physically active college students with attention-deficit/hyperactivity disorder: a randomized crossover trial.Frontiers in sports and active living · 2026Trial
- d-Amphetamine Transdermal System in Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Secondary Endpoint Results andJournal of child and adolescent psychopharmacology · 2023Trial
- Analysis of Daily Sleep Diary Measures From Multilayer Extended-Release Methylphenidate (PRC-063) Studies in Children and Adults With ADHD.Journal of attention disorders · 2022Trial
- Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adult Laboratory Classroom Study of the Efficacy and Safety of PRC-063 (Extended-Release Methylphenidate) for the Treatment of ADHD.Journal of attention disorders · 2022Trial
- Selective Effects of Methylphenidate on Attention and Inhibition in 22q11.2 Deletion Syndrome: Results From a Clinical Trial.The international journal of neuropsychopharmacology · 2022Trial
- Efficacy and Safety of Dextroamphetamine Transdermal System for the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Results from a Pivotal Phase 2 Study.Journal of child and adolescent psychopharmacology · 2022Trial
- A Phase 3 Placebo-Controlled Trial of Once-Daily 400-mg and 600-mg SPN-812 (Viloxazine Extended-Release) in Adolescents with ADHD.Psychopharmacology bulletin · 2021Trial
- A Pharmacokinetic Study of Methylphenidate Hydrochloride Multilayer Extended-Release Capsules (Aptensio XRPaediatric drugs · 2020Trial
- Long-term Effects of Multimodal Treatment on Adult Attention-Deficit/Hyperactivity Disorder Symptoms: Follow-up Analysis of the COMPAS Trial.JAMA network open · 2019Trial
- Deletion of N-ethylmaleimide-sensitive factor in dopamine D2 receptor-expressing cells impairs striatal development and dopaminergic function and induces ADHD-like behaviors in mice.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Pharmacokinetics at Different Application Sites and Dermal Safety Analysis of Dextroamphetamine Transdermal System (d-ATS) in Healthy Adults and Patients with ADHD.Advances in therapy · 2026Article
- Dose-response, net clinical benefit and optimal dose ranges of stimulants in children and adolescents with ADHD: a network meta-analysis.European child & adolescent psychiatry · 2026Article
- Investigation of the Effects of Methylphenidate on Hemodynamic Parameters in Children With ADHD.Pharmacology research & perspectives · 2026Observational
- Factors Associated with Reduced Clinical Response in Adult ADHD: The Role of Alcohol and Cannabis Use Disorders and Autism Spectrum Disorder.Journal of clinical medicine · 2026Article
- Sex differences in the response to treatment of attention deficit hyperactivity disorder.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- A retrospective single-center study on the characteristics of children with attention-deficit hyperactivity disorder requiring early drug therapy from 2013 to 2022 and changes in treatment over time.Fukushima journal of medical science · 2026Article
- Photobiomodulation as a therapeutic approach for attention-deficit/hyperactivity disorder in model rats.Lasers in medical science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Attention-deficit/hyperactivity disorder (ADHD) is a chronic psychiatric disorder characterized by hyperactivity and/or inattention and is often associated with a substantial impact on psychosocial functioning. Methylphenidate (MPH), a central nervous system stimulant, is commonly used for pharmacological treatment of adults and children with ADHD. Current practice guidelines recommend optimizing MPH dosage to individual patient needs; however, the clinical benefits of individual dose optimization compared with fixed-dose regimens remain unclear. Here we review the available literature on MPH dose optimization from clinical trials and real-world experience on ADHD management. In addition, we report safety and efficacy data from the largest MPH modified-release long-acting Phase III clinical trial conducted to examine benefits of dose optimization in adults with ADHD. Overall, MPH is an effective ADHD treatment with a good safety profile; data suggest that dose optimization may enhance the safety and efficacy of treatment. Further research is required to establish the extent to which short-term clinical benefits of MPH dose optimization translate into improved long-term outcomes for patients with ADHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.